News

February 6, 2020February 6, 2020

Follicular Lymphoma Patients in Remission for at Least 2 Years May Be Cured, Study Suggests

News

People with follicular lymphoma who are in remission for at least two years following treatment may no longer show detectable signs of the disease or possibly be cured. That finding ... Read more

February 4, 2020February 4, 2020

CAR T-cell Therapy KTE-X19 Under Review in Europe and US for Mantle Cell Lymphoma

News

The European Medicines Agency (EMA) has validated and is now reviewing Kite Pharma’s application requesting the approval of its investigational chimeric antigen receptor (CAR) T-cell therapy KTE-X19 for adult patients with relapsed or ... Read more

January 30, 2020January 30, 2020

Imbruvica Plus Rituximab Prolongs Survival in Untreated CLL/SLL Patients, Phase 3 Trial Finds

News

Imbruvica (ibrutinib) in combination with rituximab continues to prolong survival and the time without disease progression in previously untreated adults with chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma (SLL), ... Read more

January 28, 2020January 28, 2020

TG Therapeutics Seeks Accelerated FDA Approval of Umbralisib for Marginal Zone and Follicular Lymphomas

News

TG Therapeutics is seeking accelerated approval in the U.S. for its investigational oral therapy umbralisib to treat patients with marginal zone lymphoma (MZL) and follicular lymphoma (FL) who failed to ... Read more

January 23, 2020

Polivy Triple Combo Approved in Europe for Select Patients with Advanced DLBCL

News

The European Commission has conditionally approved Roche’s Polivy (polatuzumab vedotin), in combination with rituximab and bendamustine, to treat people with relapsed or refractory diffuse large B-cell lymphoma (DLBCL) who are ineligible for a hematopoietic (blood) stem cell transplant (HSCT). ... Read more

January 21, 2020January 21, 2020

Immunotherapy Showing High Response Rate in Rare Lymphoma Called ENKTL, Trial Reports

News

Treatment with CS1001, an investigational immunotherapy, shows promising anti-tumor activity against relapsed or refractory extranodal natural killer (NK)/T-cell lymphoma (ENKTL) a rare and aggressive type of non-Hodgkin’s lymphoma, early Phase 2 ... Read more

January 14, 2020January 14, 2020

MorphoSys Requests FDA Approval of Tafasitamab for Relapsed or Refractory DLBCL

News

MorphoSys is asking the U.S. Food and Drug Administration (FDA) to approve its CD19 antibody tafasitamab, in combination with Revlimid (lenalidomide), to treat patients with relapsed or refractory diffuse large B-cell lymphoma ... Read more

January 9, 2020January 15, 2020

Venclexta-rituximab Combo Shows Long-term Survival Benefits for Relapsed CLL Patients

News

A combination of Venclexta (venetoclax) and rituximab continues to significantly reduce the risk of disease progression or death in relapsed or refractory chronic lymphocytic leukemia (CLL) patients two years after completing ... Read more

January 7, 2020February 18, 2020

Bristol-Myers Seeks FDA Approval of CAR T-cell Therapy Liso-Cel for Aggressive Large B-cell Lymphomas

News

Bristol-Myers Squibb has asked the U.S. Food and Drug Administration (FDA) to approve its investigational CAR T-cell therapy lisocabtagene maraleucel (liso-cel) for people with large B-cell lymphoma who received at ... Read more

January 7, 2020February 14, 2020

FDA Grants Orphan Drug Status to CLR 131 for Lymphoplasmacytic Lymphoma Treatment

News

The U.S. Food and Drug Administration (FDA) has granted orphan drug designation to Cellectar BioSciences‘ experimental therapy CLR 131 for lymphoplasmacytic lymphoma (LPL), or Waldenström’s macroglobulinemia, a rare type of ... Read more